EFFICACY AND SAFETY OF ACETAZOLAMIDE INCONGESTIVE HEART FAILURE

Abstract

This experiment evaluated the efficacy and safety of acetazolamide in the treatment of congestive heart failure (CHF). The treatment outcomes were derived from an examination of clinical characteristics including gender distribution, weight fluctuations, comorbidities, symptoms, cardiac function, and quality of life. The study had 70 people aged between 21 and 85, with a little higher proportion of women (53%) compared to men (47%). Relative to the control group, the experimental group exhibited weight loss, improved respiration, and a reduction in symptoms such as coughing, pleural effusion, pedal edema, and crepitations. Furthermore, acetazolamide medication significantly enhanced the Minnesota Living with Heart Failure Questionnaire (MLHFQ), left ventricular ejection fraction (LVEF), and outcome measures including death, rehospitalization, partial decongestion, and effective decongestion. No significant adverse medication reactions were documented. Further research including bigger cohorts and extended follow-up periods is necessary, as the findings cannot be generalized due to the restricted sample size and brief study duration.